Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status (Q34306540)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

endometrial carcinoma

1 reference

based on heuristic

inferred from title

author name string

Pedro Fong

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Li-rong Meng

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

30 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Medical science monitor. Basic research

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

146-152

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Surgical management of early endometrial cancer: an update and proposal of a therapeutic algorithm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Risk factors for endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Finding chemo: the search for marine-based pharmaceutical drugs active against cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Major clinical research advances in gynecologic cancer in 2012.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Updates in therapy for uterine serous carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Molecular targets and targeted therapeutics in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Targeting mTOR pathways in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Multiple signal pathways in obesity-associated cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Mechanisms of mTOR inhibitor resistance in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

The physiology and pathophysiology of rapamycin resistance: implications for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Updates of mTOR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

The evolving role of adjuvant therapy in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Molecular target therapies in endometrial cancer: from the basic research to the clinic.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Adjuvant radiotherapy for stage I endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Current development of mTOR inhibitors as anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Rapamycin induces Smad activity in prostate cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Progestagens for endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

6 July 2018

Rapamycin resistance: mTORC1 substrates hold some of the answers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4189716

28 October 2018

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25266877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/25266877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25266877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of epidermal growth factor receptor expression in primary human endometrial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25266877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.12659/MSMBR.892514

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34306540&oldid=1774211302"